Gerhard Klebe studied chemistry at the University of Frankfurt/M, Germany, and obtained his doctorate in physical chemistry. After postdoctoral positions in crystallography (Grenoble, CNRS and ILL, France, Univ. of Berne, Switzerland) he was responsible for molecular modelling and crystallography at BASF-AG, Ludwigshafen, Germany. In 1996 he moved to Philipps-University of Marburg, Germany, as full professor in Pharmaceutical Chemistry. In 2005 he refused an offer from ETH Zürich, for a chair in Pharmaceutical Chemistry. Since 2020, he is retired. He served on editorial boards of several journals, was member of advisory boards of the CCDC, Cambridge, the of the Leibniz-Institute FMP in Berlin and Helmholtz-Institute in Saarbrücken. Research focus was directed toward the understanding of protein-ligand interactions, including chemical synthesis, microcalorimetry, molecular biology, crystallography, bioinformatics and software development. Internationally recognized software tools such as CoMSIA, AFMoC, DrugScore, Relibase/Cavbase or MOBILE have been developed in his laboratory. Several drug discovery projects concentrated on lead finding for neglected and poverty-related disease targets. To obtain better insight into affinity and selectivity determining features and to collect essential data for in-depth parametrization of software tools basic research has been performed on proteases, aldose reductase, kinases and hydrolases. He has written a text book on Drug Design which appeared in the German, English, and Chinese language. In 2011 the research of his group was awarded an ERC Advanced Grant on the “Chemogenomic profiling of drug-protein binding by shape, enthalpy/entropy and interaction kinetics” with particular emphasis on understanding the influence of water on ligand binding. In 2012 he received the Mannich-Medal by the German Pharmaceutical Society. Together with scientists at Bessy, HZB Berlin, a crystallography-based fragment screening beamline was established. In 2017, he was involved in the foundation of CrystalsFirst, a start-up in the fragment field. About 100 PhD students graduated from his laboratory. More than 400 scientific papers and over 1600 PDB entries emerged from his group. He organized biannually an International Workshop on New Approaches in Drug Discovery and Design and held the GRC on Computer Aided Drug Design in 2011.